Future Outlook for the Anti-Obesity Medication Market

This technical report outlines the current and projected landscape of the anti-obesity medication (AOM) market, highlighting significant growth since the introduction of Wegovy and Zepbound. The report details the surge in AOM sales, which have increased nearly tenfold since 2021, and forecasts over 40% annual growth through 2030. It discusses challenges such as patient compliance, insurance coverage limitations, and supply constraints that have impacted market expansion. The report also identifies emerging trends, including the need for unique market entry strategies and the importance of expanding treatment indications beyond obesity. It emphasizes the necessity for companies to develop diversified portfolios and prepare for substantial investments to compete effectively. The report concludes by addressing the shift towards self-pay channels, driven by limited insurance coverage, and the need for innovative pricing strategies to enhance market access and meet patient demand.